220464-68-6

Basic information

• Product Name: Methyl 3-(Bromomethyl)-4-chlorobenzoate
• Synonyms: Methyl 3-(Bromomethyl)-4-chlorobenzoate
• CAS NO: 220464-68-6
• Molecular Formula: C₉H₈BrClO₂
• Molecular Weight: 263.5156
• Mol File: 220464-68-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 314.583 °C at 760 mmHg
• Flash Point: 144.055 °C
• Appearance: /
• Density: 1.561 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: Methyl 3-(Bromomethyl)-4-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(Bromomethyl)-4-chlorobenzoate(220464-68-6)
• EPA Substance Registry System: Methyl 3-(Bromomethyl)-4-chlorobenzoate(220464-68-6)

Safety Data

• Hazardous Substances Data: 220464-68-6(Hazardous Substances Data)

Usage

General Description

Methyl 3-(Bromomethyl)-4-chlorobenzoate is a chemical compound with the molecular formula C9H8BrClO2. It is a derivative of benzoic acid and contains a methyl group, a bromomethyl group, and a chloro group attached to a benzene ring. Methyl 3-(Bromomethyl)-4-chlorobenzoate is commonly used in organic synthesis and pharmaceutical research, as well as in the production of agrochemicals and dyes. It is important to handle this chemical with care due to its potential for toxicity and irritant properties.

InChI:InChI=1/C9H8BrClO2/c1-13-9(12)6-2-3-8(11)7(4-6)5-10/h2-4H,5H2,1H3

Upstream product

• 91367-05-4 methyl 4-chloro-3-methylbenzoate 

Downstream Products

• 1260675-02-2 4-chloro-3-hydroxymethylbenzoic acid methyl ester 
• 872091-83-3 methyl 4-chloro-3-(cyanomethyl)benzoate 

Relevant articles and documents

Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

Our previously reported carboxyl-containing DPP-4 inhibitors were highly potent but were poorly bioavailable. Esters of the carboxyl analogs exhibited a significant DPP-4 potency loss albeit with enhanced oral absorption. Herein, we described identificati

Optimization of the benzamide fragment targeting the S2′ site leads to potent dipeptidyl peptidase-IV inhibitors

Our recently successful identification of benzoic acid-based DPP-4 inhibitors spurs the further quest for in-depth structure-activity relationships (SAR) study in S2′ site DPP-4. Thus novel benzamide fragments were designed to target the S

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.